FEATURES OF THE COURSE OF CORONAVIRUS DISEASE IN HEART FAILURE

Abstract

Coronavirus disease 2019 (COVID-19) is a more aggressive infection in which the risk of exacerbations increases significantly. Recent data suggest that a large proportion of deaths from COVID-19 can be attributed to cardiovascular disease, including HF [2]. HF is associated with almost a double risk of in-hospital mortality and treatment in the intensive care unit and more than threefold risk of mechanical ventilation.

The aim – to evaluate the features of the course of COVID-19 in patients with HF based on retrospective analysis.

Material and Methods. The clinical and laboratory features of the course of COVID-19 in patients with chronic HF were investigated, as well as complications, treatment results (discharge / death) based on the analysis of medical cards of 389 patients treated at the Municipal Non-Profit Enterprise "Lviv Clinical Emergency Hospital" in January and February 2021.

Results. Chronic HF was detected in 46.3 % of patients with COVID-19. These patients were more likely to have shortness of breath (88.2 % vs. 71.4 % in patients without chronic HF, p=0.074), lower saturation level (p=0.027), higher levels of leukocytosis (p=0.032), hyperglycemia (p<0.0001) and creatinine (p=0.003). Cardiac complications associated with the development of unstable angina (p<0.001), myocardial infarction (p= 0.0094), arrhythmia and conduction disorders (p<0.001) were more common in the study group of patients. They had a higher incidence of acute thrombosis (p=0.0181), pulmonary embolism (p<0.001) and hospital mortality 27.8 % vs. 10.1 % (p<0.001).

Conclusions. Coronavirus disease aggravates the course of chronic HF and manifests itself in the destabilization of the cardiovascular manifestations of the disease, an increase in thrombogenic potential, which leads to high hospital mortality.